Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-03-23

FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ZUBSOLV, a buprenorphine/naloxone product from Orexo US, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZUBSOLV (Buprenorphine hydrochloride and naloxone hydrochloride)

Snippet

SUPPL AP for ZUBSOLV (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE)